Neuraminidase inhibitors for influenza complications
Lancet
.
2014 Oct 4;384(9950):1260-1.
doi: 10.1016/S0140-6736(14)61761-X.
Authors
Chris Del Mar
1
,
Peter Doshi
2
,
Rokuro Hama
3
,
Mark Jones
4
,
Tom Jefferson
5
,
Carl Heneghan
6
,
Igho Onakpoya
6
,
Jeremy Howick
6
Affiliations
1
Centre for Research in Evidence Based Practice, Bond University, Robina, QLD 4226, Australia. Electronic address: cdelmar@bond.edu.au.
2
University of Maryland School of Pharmacy, MD, USA.
3
Japan Institute of Pharmacovigilance, Osaka, Japan.
4
School of population health, University of Queensland, QLD, Australia.
5
Cochrane Collaboration, Rome, Italy.
6
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
PMID:
25283565
DOI:
10.1016/S0140-6736(14)61761-X
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents / therapeutic use*
Humans
Influenza, Human / drug therapy*
Neuraminidase / antagonists & inhibitors*
Substances
Antiviral Agents
Neuraminidase
Grants and funding
10/80/01/DH_/Department of Health/United Kingdom